Expression Significance and Prognostic Value of GPR27 in Ovarian Cancer

This study explored the prognostic role of GPR27 and its predictive value to platinum-based therapy in ovarian cancer. A survival analysis of GPR27, and the therapeutic response to platinum in ovarian cancer was investigated using data from the cancer genome atlas (TCGA) and Gene Expression Omnibus (GEO) databases. GPR27 expression was assessed using reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry. Database analysis and RT-PCR revealed over-expression of GPR27 mRNA in ovarian cancer tissues compared to normal ovarian tissues. Ovarian cancer patients with up-regulated GPR27 transcription were associated with better overall survival and disease-free survival compared to those with downregulated GPR27 mRNA in the TCGA dataset and Kaplan-Meier plot database (<i>N</i> = 1656). GPR27 demonstrated good predictive value for pathological response in patients with ovarian cancer receiving platinum-based therapy. The predictive performance for 6-month relapse-free survival was higher in endometrioid ovarian cancer (AUC:0.804) than that in serous ovarian cancer. GPR27 protein levels were significantly up-regulated in ovarian cancer tissues compared with normal ovarian tissue, and high GPR27 protein expression correlated with early-stage TNM. ROC analysis revealed that the GPR27 protein, quantified by the immunohistochemistry score, effectively predicted the response to platinum-based therapy response with an AUC of 0.7479 in our cohort. GPR27 was up-regulated in ovarian cancer, compared with that of normal ovarian tissue, and was strongly correlated with survival outcomes and response to platinum-based therapy. GPR27 may serve as a reliable biomarker for platinum -based therapy in ovarian cancer patients.